BRPI0407814A - derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexonaca rbonil-amino)-butìrico e compostos afins como moduladores ppar para o tratamento do diabetes tipo 2 e aterosclerose - Google Patents

derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexonaca rbonil-amino)-butìrico e compostos afins como moduladores ppar para o tratamento do diabetes tipo 2 e aterosclerose

Info

Publication number
BRPI0407814A
BRPI0407814A BRPI0407814-4A BRPI0407814A BRPI0407814A BR PI0407814 A BRPI0407814 A BR PI0407814A BR PI0407814 A BRPI0407814 A BR PI0407814A BR PI0407814 A BRPI0407814 A BR PI0407814A
Authority
BR
Brazil
Prior art keywords
treatment
acid derivatives
atherosclerosis
diabetes
methyl
Prior art date
Application number
BRPI0407814-4A
Other languages
English (en)
Inventor
Christian Stapper
Dirk Gretzke
Eugen Falk
Jochen Goerlitzer
Stefanie Keil
Hans-Ludwig Schaefer
Heiner Glombik
Wolfgang Wendler
Original Assignee
Aventis Pharma Deustschland Gm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deustschland Gm filed Critical Aventis Pharma Deustschland Gm
Publication of BRPI0407814A publication Critical patent/BRPI0407814A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

"DERIVADOS DE áCIDO 3-METIL-2-(3-(2-FENILOXAZOL-4-ILMETOXI)-CICLOHEXANOCAR BONIL-AMINO)-BUTìRICO E COMPOSTOS AFINS COMO MODULADORES PPAR PARA O TRATAMENTO DO DIABETES TIPO 2 E ATEROSCLEROSE". A invenção refere-se a derivados de aminoácidos substituídos por cicloalquila, bem como aos seus sais fisiologicamente toleráveis e derivados fisiologicamente funcionais. São descritos compostos da fórmula (I), nos quais os radicais têm os significados indicados, bem como seus sais fisiologicamente toleráveis e processos para a sua preparação. Os compostos são apropriados por exemplo, para o tratamento e/ou a prevenção de distúrbios do metabolismo dos ácidos graxos e distúrbios do aproveitamento da glicose bem como de distúrbios, nos quais a resistência à insulina tem um papel importante.
BRPI0407814-4A 2003-02-27 2004-02-19 derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexonaca rbonil-amino)-butìrico e compostos afins como moduladores ppar para o tratamento do diabetes tipo 2 e aterosclerose BRPI0407814A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001578 WO2004076426A1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
BRPI0407814A true BRPI0407814A (pt) 2006-02-14

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0407814-4A BRPI0407814A (pt) 2003-02-27 2004-02-19 derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexonaca rbonil-amino)-butìrico e compostos afins como moduladores ppar para o tratamento do diabetes tipo 2 e aterosclerose
BRPI0407758-0A BRPI0407758A (pt) 2003-02-27 2004-02-19 derivados de 3-(2-fenil-oxazol-4-ilmetóxi)-ciclohexilmetóxi-acético e compostos afins como modula-dores de ppar para o tratamento de diabetes do tipo 2 e aterosclerose.
BRPI0407907-8A BRPI0407907A (pt) 2003-02-27 2004-02-19 derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos

Family Applications After (2)

Application Number Title Priority Date Filing Date
BRPI0407758-0A BRPI0407758A (pt) 2003-02-27 2004-02-19 derivados de 3-(2-fenil-oxazol-4-ilmetóxi)-ciclohexilmetóxi-acético e compostos afins como modula-dores de ppar para o tratamento de diabetes do tipo 2 e aterosclerose.
BRPI0407907-8A BRPI0407907A (pt) 2003-02-27 2004-02-19 derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos

Country Status (34)

Country Link
US (5) US7365084B2 (pt)
EP (3) EP1599455B1 (pt)
JP (3) JP2006519199A (pt)
KR (3) KR20050105492A (pt)
CN (3) CN100439347C (pt)
AR (3) AR043432A1 (pt)
AT (3) ATE365159T1 (pt)
AU (3) AU2004215673B2 (pt)
BR (3) BRPI0407814A (pt)
CA (3) CA2517381A1 (pt)
CL (2) CL2004000391A1 (pt)
CO (2) CO5690580A2 (pt)
DE (4) DE10308355A1 (pt)
DK (3) DK1599453T3 (pt)
EC (2) ECSP055985A (pt)
ES (3) ES2287700T3 (pt)
HR (3) HRP20050742A2 (pt)
IL (2) IL170314A (pt)
MA (3) MA27736A1 (pt)
MX (3) MXPA05008995A (pt)
NO (3) NO20054398L (pt)
OA (2) OA13034A (pt)
PA (1) PA8596801A1 (pt)
PE (3) PE20050293A1 (pt)
PL (3) PL378437A1 (pt)
PT (3) PT1599453E (pt)
RS (1) RS20050594A (pt)
RU (3) RU2005130002A (pt)
SA (1) SA04250153A (pt)
TN (2) TNSN05206A1 (pt)
TW (3) TW200510352A (pt)
UY (2) UY28210A1 (pt)
WO (3) WO2004076426A1 (pt)
ZA (2) ZA200505768B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
WO2008018138A1 (fr) 2006-08-10 2008-02-14 Wood One Co., Ltd. Composition hypoglycémique contenant un composant issu de l'écorce d'un arbre appartenant au genre acacia
CN105732376A (zh) 2007-08-16 2016-07-06 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
NZ587261A (en) 2008-02-29 2012-05-25 Nissan Chemical Ind Ltd Process for producing thiophene compound and intermediate thereof
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
WO2019117317A1 (ja) 2017-12-13 2019-06-20 キヤノン株式会社 カートリッジ及び画像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
HUP0301101A3 (en) 1996-12-31 2009-03-30 Reddy S Res Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化１，２，４−チアジアジン誘導体、その調製及び使用
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
KR100613175B1 (ko) * 1998-08-27 2006-08-17 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
KR100693771B1 (ko) * 1999-04-28 2007-03-12 사노피-아벤티스 도이칠란트 게엠베하 Ｐｐａｒ 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
CZ20013833A3 (cs) 1999-04-28 2002-02-13 Aventis Pharma Deutschland Gmbh Deriváty kyselin se dvěma arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
EP1194146B1 (en) 1999-06-18 2006-07-19 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
AU5784000A (en) 1999-07-09 2001-01-30 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
JP2003506365A (ja) 1999-07-29 2003-02-18 イーライ・リリー・アンド・カンパニー ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン：セロトニンアゴニスト
CZ2002767A3 (cs) * 1999-09-01 2002-06-12 Aventis Pharma Deutschland Gmbh Sulfonylkarboxamidové deriváty, způsob jejich přípravy a jejich pouľití jako léčiv
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
DE60008921T2 (de) 1999-12-03 2005-01-20 Astrazeneca Ab Kristalline form von (s)-2-ethoxy-3-4-(2-4-methansulfonyloxyphenyl-ethoxy)phenyl]propansäure
IL151368A0 (en) 2000-03-31 2003-04-10 Probiodrug Ag Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions
US6770133B2 (en) 2000-04-25 2004-08-03 Kyorin Pharmaceutical Co., Ltd. Stable crystal of thiazolidinedione derivative and process for producing the same
DK1277736T3 (da) 2000-04-28 2007-10-01 Asahi Kasei Pharma Corp Hidtil ukendte bicykliske forbindelser
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
YU91002A (sh) 2000-06-09 2006-05-25 Aventis Pharma Deutschland Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
CA2418104A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2001284658A1 (en) 2000-08-23 2002-03-13 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
RS50864B (sr) 2000-12-21 2010-08-31 Sanofi-Aventis Deutschland Gmbh. Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
KR100635315B1 (ko) * 2000-12-25 2006-10-18 오노 야꾸힝 고교 가부시키가이샤 디히드로나프탈렌 유도체 화합물 및 이 화합물을 유효성분으로 하는 약제
BR0207285A (pt) * 2001-02-15 2004-02-10 Pfizer Producs Inc Agonistas de ppar
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
KR20040030658A (ko) * 2001-06-07 2004-04-09 일라이 릴리 앤드 캄파니 페록시좀 증식제 활성화 수용체의 조절제
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
KR100915108B1 (ko) 2001-08-31 2009-09-03 사노피-아벤티스 도이칠란트 게엠베하 Ｐｐａｒ-활성화제로서의 디아릴사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물
WO2003066581A1 (en) 2002-02-05 2003-08-14 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
EP1599452B1 (de) 2007-06-20
HRP20050744A2 (en) 2006-09-30
CO5690580A2 (es) 2006-10-31
CN1753879A (zh) 2006-03-29
US7335671B2 (en) 2008-02-26
DK1599453T3 (da) 2009-08-24
KR20050106461A (ko) 2005-11-09
WO2004076428A1 (de) 2004-09-10
CL2004000392A1 (es) 2005-04-22
US20080167354A1 (en) 2008-07-10
DE502004004139D1 (de) 2007-08-02
NO20054396D0 (no) 2005-09-22
US20050215596A1 (en) 2005-09-29
ECSP055986A (es) 2006-01-16
WO2004076426A1 (de) 2004-09-10
PL378130A1 (pl) 2006-03-06
ATE365159T1 (de) 2007-07-15
CA2516620A1 (en) 2004-09-10
CN1753881A (zh) 2006-03-29
MA27742A1 (fr) 2006-02-01
ATE430738T1 (de) 2009-05-15
OA13035A (en) 2006-11-10
UY28209A1 (es) 2004-09-30
ATE435217T1 (de) 2009-07-15
CA2517386A1 (en) 2004-09-10
CN1756748A (zh) 2006-04-05
JP2006519194A (ja) 2006-08-24
ECSP055985A (es) 2006-01-16
RS20050594A (en) 2007-12-31
DE502004009690D1 (de) 2009-08-13
EP1599455A1 (de) 2005-11-30
TW200508210A (en) 2005-03-01
PL377735A1 (pl) 2006-02-20
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
NO20054408D0 (no) 2005-09-22
AR043432A1 (es) 2005-07-27
AU2004215672B2 (en) 2010-01-07
OA13034A (en) 2006-11-10
EP1599453A1 (de) 2005-11-30
DK1599455T3 (da) 2009-11-09
MXPA05008951A (es) 2005-11-04
RU2005129995A (ru) 2006-01-27
JP2006519193A (ja) 2006-08-24
KR20050106462A (ko) 2005-11-09
EP1599452A1 (de) 2005-11-30
AU2004215673A1 (en) 2004-09-10
HRP20050742A2 (en) 2006-09-30
PT1599455E (pt) 2009-09-29
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
PE20050293A1 (es) 2005-05-24
US7872034B2 (en) 2011-01-18
EP1599453B1 (de) 2009-05-06
TW200510352A (en) 2005-03-16
AU2004215672A1 (en) 2004-09-10
BRPI0407907A (pt) 2006-02-14
CN100398526C (zh) 2008-07-02
US20050101637A1 (en) 2005-05-12
AU2004215673B2 (en) 2009-10-01
PL378437A1 (pl) 2006-04-03
UY28210A1 (es) 2004-09-30
US7365084B2 (en) 2008-04-29
US20080015238A1 (en) 2008-01-17
MA27737A1 (fr) 2006-02-01
MA27736A1 (fr) 2006-02-01
ZA200505768B (en) 2005-11-23
RU2005129992A (ru) 2006-02-10
CL2004000391A1 (es) 2005-01-07
JP2006519199A (ja) 2006-08-24
CA2517381A1 (en) 2004-09-10
BRPI0407758A (pt) 2006-02-14
ZA200505765B (en) 2006-05-31
DE502004009453D1 (de) 2009-06-18
PE20040959A1 (es) 2005-01-17
ES2329366T3 (es) 2009-11-25
CN100439347C (zh) 2008-12-03
MXPA05008995A (es) 2005-10-18
RU2005130002A (ru) 2006-01-27
MXPA05008988A (es) 2005-10-18
ES2326418T3 (es) 2009-10-09
EP1599455B1 (de) 2009-07-01
IL170314A (en) 2010-11-30
ES2287700T3 (es) 2007-12-16
NO20054396L (no) 2005-11-11
AR043427A1 (es) 2005-07-27
TNSN05204A1 (en) 2007-06-11
TNSN05206A1 (en) 2007-06-11
CO5690578A2 (es) 2006-10-31
DE10308355A1 (de) 2004-12-23
TW200500349A (en) 2005-01-01
KR20050105492A (ko) 2005-11-04
US7259177B2 (en) 2007-08-21
CN100439345C (zh) 2008-12-03
AU2004215677B2 (en) 2010-01-07
PT1599453E (pt) 2009-07-14
US20040209920A1 (en) 2004-10-21
NO20054398L (no) 2005-11-02
NO20054398D0 (no) 2005-09-22
AU2004215677A1 (en) 2004-09-10
AR043433A1 (es) 2005-07-27
DK1599452T3 (da) 2007-10-01
PE20050292A1 (es) 2005-05-24
WO2004076427A1 (de) 2004-09-10
PT1599452E (pt) 2007-09-12
SA04250153A (ar) 2005-12-03

Similar Documents

Publication Publication Date Title
BRPI0407814A (pt) derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexonaca rbonil-amino)-butìrico e compostos afins como moduladores ppar para o tratamento do diabetes tipo 2 e aterosclerose
BR0212158A (pt) Derivados de diarilcicloalquila, processos para a sua preparação e sua aplicação como ativadores de ppar
BR0111457A (pt) Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
BR0312697A (pt) Benzoiluréias substituìdas heterociclicamente, processo para a sua preparação e sua aplicação como medicamento
BR0009641A (pt) Derivados de 1,4-benzotiazepin-1,1-dióxido, substituìdos com radicais de açúcar, processo para produção dos mesmos, medicamentos contendo esses compostos e sua utilização
BR0317458A (pt) EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
BR0210008A (pt) Derivados de feniluréia substituìdos com carboxamida, processos para produção dos mesmos como medicamentos
BRPI0407504A (pt) heterociclos n-arila substituìdo, processo para sua preparação e uso dos mesmos como medicamentos
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BRPI0409916A (pt) ácidos carboxìlicos substituìdos com fenila
BR0208150A (pt) Antagonistas de mch e sua aplicação no tratamento da obesidade
BR0308188A (pt) Forma de administração a ser aplicada oralmente, para substâncias ativas básicas de difìcil solubilidade
BRPI0805826A2 (pt) compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento
BRPI0514741A (pt) derivados de hexahidro-pirazino[1, 2-a]pirimidina-4, 7-diona substituìdos por aminoácidos
BRPI0507104A (pt) n-ciclohexilimidazolinonas substituìdas com efeito modulador de mch
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
NO20063865L (no) Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
BRPI0509517A (pt) derivados de oxadiazolona como agonistas de ppar delta
BRPI0514359A (pt) derivados de amida do ácido n-(fenil-oxazol-4-il-metoximetil)-ciclohexil-succìnico e compostos relacionados que são usados como ligantes ppar (receptores ativados - proliferadores de peroxisoma) para o tratamento de hiperlipidemia e diabetes
BR0315574A (pt) Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
BRPI0407901A (pt) derivados de diarilcicloalquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos
NO20063859L (no) Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter
NO20081681L (no) N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.